• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·000705.SZ
Share

Zhejiang Zhenyuan Share Co.,Ltd. Stocks

CN¥ 6.32Last Updated 14.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 306.71M

CN¥ 6.32
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Shaoxing, China, Zhejiang Zhenyuan Share Co., Ltd. is a pharmaceutical entity with operations extending across China and into global markets. Established in 1752, the company provides a wide array of pharmaceutical offerings. These include various traditional Chinese medicines (such as patent medicines, raw materials, and herbal preparations), alongside modern chemical preparations, active pharmaceutical ingredients, biochemical compounds, anesthetics, psychotropic drugs, medical equipment, and chemical reagents. Its diverse product line is marketed under the Zhenyuan and Zhenyuantang brand names. The firm primarily caters to the pharmaceutical commerce and health service industries.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 18:12

Oil at $87, Houthi attacks, strikes on UAE tankers: What’s happening in the Middle East?

14.07.2026 17:48

Consumer inflation in the U.S. turned out to be much lower than expected

14.07.2026 17:40

Nebius closed a $1 billion deal with a startup founded by former Google AI developers

14.07.2026 17:25

SpaceX Lost More Than $800 Billion in Market Value in a Month: Shares Are Close to Their IPO Price

14.07.2026 17:14

IBM shares plummeted 20% following a warning about weak quarterly results

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026